Biodexa Pharmaceuticals (BDRX) Competitors $3.85 +0.23 (+6.35%) (As of 09:15 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends BDRX vs. DRMA, BON, KRBP, PBLA, SXTC, CYTO, TRVN, ADTX, TFFP, and ASLNShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Dermata Therapeutics (DRMA), Bon Natural Life (BON), Kiromic BioPharma (KRBP), Panbela Therapeutics (PBLA), China SXT Pharmaceuticals (SXTC), Altamira Therapeutics (CYTO), Trevena (TRVN), Aditxt (ADTX), TFF Pharmaceuticals (TFFP), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Dermata Therapeutics Bon Natural Life Kiromic BioPharma Panbela Therapeutics China SXT Pharmaceuticals Altamira Therapeutics Trevena Aditxt TFF Pharmaceuticals ASLAN Pharmaceuticals Biodexa Pharmaceuticals (NASDAQ:BDRX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations. Does the media favor BDRX or DRMA? In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than Dermata Therapeutics. MarketBeat recorded 5 mentions for Biodexa Pharmaceuticals and 3 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 0.77 beat Biodexa Pharmaceuticals' score of 0.44 indicating that Dermata Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Biodexa Pharmaceuticals Neutral Dermata Therapeutics Positive Does the MarketBeat Community believe in BDRX or DRMA? Dermata Therapeutics received 4 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 50.00% of users gave Dermata Therapeutics an outperform vote. CompanyUnderperformOutperformBiodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesDermata TherapeuticsOutperform Votes550.00% Underperform Votes550.00% Is BDRX or DRMA more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Dermata Therapeutics N/A -247.39%-179.72% Do analysts prefer BDRX or DRMA? Biodexa Pharmaceuticals currently has a consensus target price of $200.00, suggesting a potential upside of 5,094.81%. Dermata Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 430.04%. Given Biodexa Pharmaceuticals' higher possible upside, equities analysts clearly believe Biodexa Pharmaceuticals is more favorable than Dermata Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in BDRX or DRMA? 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 9.4% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings & valuation, BDRX or DRMA? Biodexa Pharmaceuticals has higher revenue and earnings than Dermata Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$470K0.98-$7.66MN/AN/ADermata TherapeuticsN/AN/A-$7.80M-$16.41-0.07 Which has more volatility and risk, BDRX or DRMA? Biodexa Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. SummaryBiodexa Pharmaceuticals beats Dermata Therapeutics on 9 of the 12 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$462,000.00$6.31B$4.81B$8.62BDividend YieldN/A8.11%7.42%4.07%P/E RatioN/A9.08115.5117.06Price / Sales0.98367.581,321.5686.87Price / CashN/A50.7536.8135.17Price / Book0.049.746.336.06Net Income-$7.66M$149.16M$112.82M$222.92M7 Day Performance-25.68%-4.04%112.40%0.14%1 Month Performance-32.46%-3.60%116.90%5.21%1 Year PerformanceN/A30.44%155.77%25.70% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals2.8103 of 5 stars$3.85+6.4%$200.00+5,094.8%N/A$462,000.00$470,000.000.0021Gap UpDRMADermata Therapeutics2.2155 of 5 stars$1.12-5.9%N/A-89.3%$1.69MN/A-0.078BONBon Natural LifeN/A$1.42+5.2%N/A-67.0%$1.67M$29.52M0.00100Gap UpKRBPKiromic BioPharmaN/A$1.00flatN/A+354.3%$1.58MN/A-0.1535PBLAPanbela Therapeutics1.2456 of 5 stars$0.33+6.6%N/A-97.2%$1.58MN/A0.007High Trading VolumeSXTCChina SXT Pharmaceuticals1.1903 of 5 stars$0.39-9.4%N/A-79.8%$1.57M$1.93M0.0090Positive NewsCYTOAltamira Therapeutics0.8924 of 5 stars$0.46+7.1%N/A-91.9%$1.55M$320,000.000.0020Gap UpHigh Trading VolumeTRVNTrevena1.4512 of 5 stars$1.68-0.6%N/A-88.4%$1.45M$443,000.00-0.0440Analyst RevisionNews CoverageGap UpADTXAditxt0.3941 of 5 stars$0.32-8.5%N/A-99.8%$1.36M$640,000.000.0047Gap DownTFFPTFF Pharmaceuticals1.942 of 5 stars$0.38-76.4%N/A-94.9%$1.30M$730,000.00-0.0519Short Interest ↑Gap DownHigh Trading VolumeASLNASLAN Pharmaceuticals1.1814 of 5 stars$0.60flatN/AN/A$1.23M$12M-0.0330 Related Companies and Tools Related Companies Dermata Therapeutics Competitors Bon Natural Life Competitors Kiromic BioPharma Competitors Panbela Therapeutics Competitors China SXT Pharmaceuticals Competitors Altamira Therapeutics Competitors Trevena Competitors Aditxt Competitors TFF Pharmaceuticals Competitors ASLAN Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BDRX) was last updated on 11/18/2024 by MarketBeat.com Staff From Our Partners“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
